NCT00435695View on ClinicalTrials.gov

Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males

PHASE1CompletedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Healthy SubjectsDepressive Disorder and Anxiety Disorders

Interventions

DRUG

GSK163090

Trial Locations (1)

M5T 1R8

GSK Investigational Site, Toronto

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00435695 - Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males | Biotech Hunter | Biotech Hunter